KOC
CPRX

Koss-Olinger Consulting’s Catalyst Pharmaceutical CPRX Stock Holding History

Koss-Olinger Consulting’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-22,660
Closed -$291K – 243
2022
Q3 		$291K Buy
22,660
+3,752
+20% +$44.5K 0.05% 157
2022
Q2 		$133K Buy
18,908
+3,824
+25% +$28K 0.02% 170
2022
Q1 		$125K Buy
15,084
+4,664
+45% +$33K 0.02% 189
2021
Q4 		$71K Buy
+10,420
New +$68.5K 0.01% 208

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Koss-Olinger Consulting's CPRX Position: Q4 2022 in Review

Koss-Olinger Consulting sold out of Catalyst Pharmaceutical (CPRX) in Q4 2022, closing a stake of 22,660 shares — an estimated $291K sold.

Koss-Olinger Consulting first reported a position in CPRX in Q4 2021 and held it in 4 quarters. The position peaked at $291K in Q3 2022. 257 funds tracked by Wall St. Rank hold CPRX as of Q4 2022.

  • Koss-Olinger Consulting reported no remaining Catalyst Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Koss-Olinger Consulting sold 22,660 Catalyst Pharmaceutical shares in Q4 2022, an estimated $291K.
  • Koss-Olinger Consulting first reported a position in Catalyst Pharmaceutical in Q4 2021 and held it in 4 quarters.
  • Koss-Olinger Consulting's Catalyst Pharmaceutical position peaked at $291K in Q3 2022.
  • 257 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2022.

Based on Koss-Olinger Consulting's 13F filing for Q4 2022, filed 14 Feb 2023.